Xencor’s (XNCR) Sell Rating Reiterated at Zacks Investment Research

Xencor (NASDAQ:XNCR)‘s stock had its “sell” rating reiterated by Zacks Investment Research in a research report issued to clients and investors on Saturday.

According to Zacks, “Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. “

Other research analysts also recently issued reports about the company. BidaskClub raised Xencor from a “strong sell” rating to a “sell” rating in a report on Thursday, December 7th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $35.00 target price on shares of Xencor in a report on Sunday, November 12th. Cantor Fitzgerald began coverage on Xencor in a report on Wednesday, November 29th. They set an “overweight” rating and a $33.00 target price on the stock. ValuEngine downgraded Xencor from a “hold” rating to a “sell” rating in a report on Monday, October 23rd. Finally, Canaccord Genuity set a $36.00 target price on Xencor and gave the stock a “buy” rating in a report on Monday, October 23rd. Three analysts have rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $30.80.

Shares of Xencor (NASDAQ:XNCR) traded down $0.26 on Friday, reaching $22.50. The company’s stock had a trading volume of 102,065 shares, compared to its average volume of 158,150. The firm has a market cap of $1,068.83, a P/E ratio of -22.50 and a beta of 2.09. Xencor has a 52-week low of $18.55 and a 52-week high of $28.64.

In other Xencor news, major shareholder John S. Stafford III acquired 50,000 shares of the company’s stock in a transaction dated Thursday, November 2nd. The shares were bought at an average cost of $19.58 per share, with a total value of $979,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder John S. Stafford III acquired 150,000 shares of the company’s stock in a transaction dated Friday, October 27th. The stock was acquired at an average cost of $19.81 per share, for a total transaction of $2,971,500.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 278,535 shares of company stock worth $5,526,936 over the last ninety days. Company insiders own 4.03% of the company’s stock.

Several large investors have recently made changes to their positions in XNCR. Great West Life Assurance Co. Can lifted its stake in shares of Xencor by 158.9% in the 3rd quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 4,005 shares during the period. SG Americas Securities LLC lifted its stake in shares of Xencor by 62.6% in the 2nd quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 3,252 shares during the period. Legal & General Group Plc lifted its stake in shares of Xencor by 4.5% in the 2nd quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 385 shares during the period. Principal Financial Group Inc. acquired a new position in shares of Xencor in the 3rd quarter valued at about $201,000. Finally, Citadel Advisors LLC acquired a new position in shares of Xencor in the 2nd quarter valued at about $224,000. 77.50% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/13/xencors-xncr-sell-rating-reiterated-at-zacks-investment-research.html.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply